Home Amedeo

Flying Publisher   

 
 
Rules

Press Releases

Contributions

Archive

Video


 


 
 

Boehringer Ingelheim in HIV/AIDS

Boehringer Ingelheim is committed to improving HIV/AIDS therapy by providing patients and physicians with innovative antiretroviral drugs.

VIRAMUNE® (Nevirapine) - the first non-nucleoside reverse transcriptase inhibitor (NNRTI) - is available in about 120 countries as an effective part of combination therapy of HIV-1. Viramune® has demonstrated its proven benefit in various clinical trials. The only non-nucleoside reverse transcriptase inhibitor (NNRTI) in US Food and Drug Administration (FDA) pregnancy category B, VIRAMUNE® has been established as a cornerstone of therapy. This is particularly true in the treatment of HIV-positive women of child-bearing age. Nevirapine has therefore become one of the most prescribed antiretrovirals worldwide.

APTIVUS® - a non-peptidic protease inhibitor, blocks the viral protease, an enzyme needed to complete HIV replication. In co-administration with ritonavir, APTIVUS® is indicated for combined antiretroviral treatment of HIV infection in highly treatment-experienced patients with resitance to multiple protease inhibitors.

Both therapies are supported by an ongoing HIV trial programme that includes the ARTEN and the VERxVE trail.

The ARTEN trial is designed to compare the efficacy and safety of Viramune® (nevirapine) dosed once daily (QD) or twice daily (BID), versus atazanavir/ritonavir, a once-daily dosed protease inhibitor (PI) in treatment naïve patients. Both agents are combined with a background regimen including tenofovir and emtricitabine (Truvada®). The recruitment of the almost 600 patients has been completed in February 2008. First results will be available in mid 2009.

The VERxVE study - a randomized, double blind, double placebo, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD Viramune Extended Release formulation in comparison to 200 mg BID Viramune immediate release in combination with Truvada in antiretroviral therapy naïve HIV-1 infected patients - started this year and will enroll approximately 1,000 HIV-positive treatment-naïve patients in 18 countries.

Our research activities in HIV are aimed at developing new treatment options for all patients infected with HIV, especially those who have failed prior therapy due to the development of drug resistance. Boehringer Ingelheim's research in this area focuses on novel therapeutic principles with potential for use in combination with other antiretroviral medicines. Several small molecule therapies are currently being pursued in preclinical research and offer promise as future treatments for both treatment-naïve and treatment-experienced HIV patients.

One of the main Boehringer Ingelheim research centres is based in Laval, Canada, where new state-of-the-art laboratories were inaugurated in June 2008. They are an extensive addition to the existing research site and are designed to support further research into treatments for serious infectious diseases. As one of the four principal research centres for Boehringer Ingelheim worldwide, the Laval facility focuses on the discovery of new treatments for Hepatitis C and the HI virus (HIV). The new laboratories will allow Boehringer Ingelheim to further strengthen its research activities and complement the existing product portfolio.

 

Social Commitment

In improving access to anti-AIDS drugs, Boehringer Ingelheim acknowledges its special responsibility as a research-driven pharmaceutical company in the fight against the HIV/AIDS pandemic. Our VIRAMUNE® Donation Programme, set up in 2000 to help the countries most in need of support in combating HIV/AIDS, targets the prevention of mother-to-child trans-mission (pMTCT) of the HIV-1 virus during birth. The amount of drugs supplied under the VDP is now over 1,5 million mother-child pair doses, with the millionth dose going to Malawi in 2007.

 

About Boehringer Ingelheim

Boehringer Ingelheim is a research-driven group of companies dedicated to researching and developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.

Its business consists of Human Pharmaceuticals and Animal Health. The company focuses on innovative drugs and treatments that represent major therapeutic advances.

Excellence in innovation and technology guides its actions in all areas. Its products have long been highly successful in the treatment of central nervous system, respiratory, cardivascular, urological and virological disorders. In addition, it has successfully advanced its research in thrombo-embolic, metabolic and oncological diseases.

Boehringer Ingelheim has 39,800 employees in 135 affiliated companies worldwide. We have research and development facilites in ten countries and production plants in more than 20 countries. It is headquartered in Ingelheim, Germany.

 

Amedeo Prize 2008

Boehringer Ingelheim has made a contribution of 5.000 Euro to the Amedeo Prize 2008.


 

 
 
  Design: